R
Rob Knight
Researcher at University of California, San Diego
Publications - 1188
Citations - 322479
Rob Knight is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Microbiome & Biology. The author has an hindex of 201, co-authored 1061 publications receiving 253207 citations. Previous affiliations of Rob Knight include Anschutz Medical Campus & University of Sydney.
Papers
More filters
Journal ArticleDOI
Interacting Symbionts and Immunity in the Amphibian Skin Mucosome Predict Disease Risk and Probiotic Effectiveness
Douglas C. Woodhams,Hannelore Brandt,Simone Baumgartner,Jos Kielgast,Eliane Küpfer,Ursina Tobler,Leyla Alexandra Davis,Benedikt R. Schmidt,Christian Bel,Sandro Hodel,Rob Knight,Valerie J. McKenzie +11 more
TL;DR: It is found that antifungal function of the amphibian skin mucosome predicts the prevalence of infection with the fungal pathogen in natural populations, and is linked to survival in laboratory exposure experiments.
Journal ArticleDOI
Translocation of Viable Gut Microbiota to Mesenteric Adipose Drives Formation of Creeping Fat in Humans
Connie W.Y. Ha,Anthony Martin,Gregory D. Sepich-Poore,Baochen Shi,Yizhou Wang,Kenneth Gouin,Gregory Humphrey,Karenina Sanders,Yasiru Ratnayake,Kelvin S.L. Chan,Gustaf Hendrick,J.R. Caldera,Christian Arias,Jacob E. Moskowitz,Shannan J. Ho Sui,Shaohong Yang,David M. Underhill,Matthew J. Brady,Simon R.V. Knott,Kelly Kaihara,Michael J. Steinbaugh,Huiying Li,Dermot P.B. McGovern,Rob Knight,Phillip Fleshner,Suzanne Devkota +25 more
TL;DR: A subset of mucosal-associated gut bacteria that consistently translocated and remained viable in CrF in CD ileal surgical resections is discovered, and Clostridium innocuum is identified as a signature of this consortium with strain variation between mucosal and adipose isolates, suggesting preference for lipid-rich environments.
Journal ArticleDOI
Open-Source Sequence Clustering Methods Improve the State Of the Art
Evguenia Kopylova,Jose A. Navas-Molina,Céline Mercier,Zhenjiang Zech Xu,Frédéric Mahé,Yan He,Hongwei Zhou,Torbjørn Rognes,Torbjørn Rognes,J. Gregory Caporaso,Rob Knight +10 more
TL;DR: The performance of recently released state-of-the-art open-source clustering software products, namely, OTUCLUST, Swarm, SUMACLUST, and SortMeRNA, against current principal options in QIIME, hierarchical clustering methods in mothur, and USEARCH’s most recent clustering algorithm, UPARSE are evaluated.
Posted ContentDOI
American Gut: an Open Platform for Citizen-Science Microbiome Research
Daniel McDonald,Embriette R. Hyde,Justine W. Debelius,James T. Morton,Antonio Gonzalez,Gail Ackermann,Alexander A. Aksenov,Alexander A. Aksenov,Bahar Behsaz,Caitriona Brennan,Yingfeng Chen,Lindsay DeRight Goldasich,Pieter C. Dorrestein,Pieter C. Dorrestein,Robert R. Dunn,Ashkaan K. Fahimipour,James Gaffney,Jack A. Gilbert,Grant Gogul,Jessica L. Green,Philip Hugenholtz,Greg Humphrey,Curtis Huttenhower,Curtis Huttenhower,Matthew A. Jackson,Stefan Janssen,Dilip V. Jeste,Lingjing Jiang,Scott T. Kelley,Dan Knights,Tomasz Kosciolek,Joshua Ladau,Jeff Leach,Clarisse Marotz,Dmitry Meleshko,Alexey V. Melnik,Alexey V. Melnik,Jessica L. Metcalf,Hosein Mohimani,Emmanuel Montassier,Emmanuel Montassier,Jose A. Navas-Molina,Tanya T. Nguyen,Shyamal D. Peddada,Pavel A. Pevzner,Katherine S. Pollard,Gholamali Rahnavard,Gholamali Rahnavard,Adam Robbins-Pianka,Naseer Sangwan,Joshua Shorenstein,Larry Smarr,Larry Smarr,Se Jin Song,Tim D. Spector,Austin D. Swafford,Varykina G. Thackray,Luke R. Thompson,Anupriya Tripathi,Yoshiki Vázquez-Baeza,Alison Vrbanac,Paul E. Wischmeyer,Elaine Wolfe,Qiyun Zhu,Rob Knight,Rob Knight +65 more
TL;DR: It is shown that a citizen-science, self-selected cohort shipping samples through the mail at room temperature recaptures many known microbiome results from clinically collected cohorts and reveals new ones, and that the extent of microbiome change after events such as surgery can exceed differences between distinct environmental biomes.
Journal ArticleDOI
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Paul G. Richardson,Edie Weller,Sundar Jagannath,David Avigan,Melissa Alsina,Robert L. Schlossman,Amitabha Mazumder,Nikhil C. Munshi,Irene M. Ghobrial,Deborah Doss,Diane Warren,Laura E. Lunde,Mary McKenney,Carol Delaney,Constantine S. Mitsiades,Teru Hideshima,William S. Dalton,Rob Knight,Dixie-Lee Esseltine,Kenneth C. Anderson +19 more
TL;DR: Lenalidomide plus bortezomib was well tolerated and showed promising activity with durable responses in patients with relapsed and relapsed/refractory multiple myeloma, including patients previously treated with lenalidomides, bortzomib, and/or thalidomid.